Nathaniel Wilson
Assistant Professor of Hematology and Medical Oncology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Year:
2025
Purpose: Treatment outcomes in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) remains dismal. On the basis of both extensive preclinical data and emerging clinical data, treatment with bromodomain and extra-terminal domain inhibitors (BETi) is a potential approach for patients with high-risk myeloid malignancies. Patients and Methods: We conducted a phase I trial to study the safety and efficacy of PLX51107 (BETi) and azacitidine combination therapy in patients with R/R AML and high-risk (HR) MDS and studied mechanisms of resistance to the combination therapy. Results: Thirty-seven patients with HR R/R MDS ( n = 4) and R/R AML ( n = 33) were treated. Sixteen patients (43%) had MECOM gene rearrangement and 7 other patients had TP53 mutation. Median prior number of therapies was three (range 1–9); 97% had received prior hypomethylating agent and 84% prior venetoclax. Overall response rate was 8/37 (22%): complete remission with incomplete platelet recovery ( n = 1); morphologic leukemia-free state ( n = 2); hematologic improvement ( n = 5). The most common nonhematologic toxicities were febrile neutropenia and pneumonia in 12 (32%) patients each; 6 patients (17%) had severe hyperbilirubinemia. RNA-sequencing analysis of mononuclear cells harvested on treatment (day 3) versus pretreatment showed significant changes in mRNA expressions in responders: downregulation of MYC , BCL2 , IL7R , and CDK6 and upregulation of HEXIM1 , CD93 , DCXR , and CDKN1A . Immunoblot analyses confirmed reduction in protein levels of c-Myc, CDK6, BCL2, and BCL-xL, and induction of BRD4 and HEXIM1 protein levels in responders. Conclusions: In a heavily pretreated patient cohort with R/R MDS and AML, PLX51107+ azacitidine was well-tolerated and resulted in modest clinical benefit.
Year:
2025
Year:
2023
Year:
2023
Non‐clear cell renal cell carcinoma (nccRCC) makes up nearly one quarter of all RCC subtypes, commonly impacts younger patients, and is often metastatic at presentation. Compared to clear‐cell RCC (ccRCC), nccRCC typically has a worse prognosis in the metastatic setting, with overall survival durations that are ~10 months shorter. The nccRCC consists of a wide range of different histological subtypes, the majority of which are composed of papillary, chromophobe, renal medullary carcinoma, translocation RCC, collecting duct carcinoma and unclassified RCC. Most clinical trials have either excluded or only included small numbers of patients with nccRCC; owing to the lack of prospective studies focusing on this population, data on response rates and survival outcomes are lacking. NccRCC treatment is a nascent field with various therapeutic modalities and combinations under investigation, often based on data extrapolated from therapeutic studies in ccRCC. We herein review the use and outcomes of cytotoxic chemotherapy, various combination modalities of tyrosine kinase inhibitors and immune checkpoint inhibitors, and targeted agents. We discuss active ongoing clinical trials for patients with nccRCC and future directions in the treatment of this rare disease. Historically, treatment for nccRCC has been adopted from the standard of care for patients with ccRCC, although these treatments are less effective in the nccRCC population. As we begin to understand the underlying biology of these tumors, clinical trials have been able to slowly accrue and include more patients with various subtypes of nccRCC. There remains much room for improvement in this area of need, but there is hope on the horizon.
Year:
2023
Year:
2023
Collaborators (27)
Gautam Borthakur
The University of Texas MD Anderson Cancer Center
Katherine Kurnit
Assistant Professor
University of Chicago Medicine
Kaitlin J Basham
Assistant Professor
University of Utah
Jianjun Gao
Assistant Professor
The University of Texas MD Anderson Cancer Center
Jayastu Senapati
Assistant professor
The University of Texas MD Anderson Cancer Center
Daniel Frigo
Scientific Director of Research
The University of Texas MD Anderson Cancer Center
Ghayas C. Issa
Assistant Professor
The University of Texas MD Anderson Cancer Center
Marina Konopleva
Professor
Albert Einstein College of Medicine
Eleonora Dondossola
The University of Texas MD Anderson Cancer Center
Elshad Hasanov
Assistant Professor
The Ohio State University Comprehensive Cancer Center
Paul Corn
Chair
The University of Texas MD Anderson Cancer Center
Shannon Westin
The University of Texas MD Anderson Cancer Center
Joseph D. Khoury
University of Nebraska Medical Center
Jan A. Burger
The University of Texas MD Anderson Cancer Center
Koji Sasaki
Chair and Professor
The University of Texas MD Anderson Cancer Center
Nitin Jain
The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Professor of Medicine, Chief Section of AML
The University of Texas MD Anderson Cancer Center
Kapil Bhalla
-
Naveen Pemmaraju
The University of Texas MD Anderson Cancer Center
Nicholas J. Short
-
Warren Fiskus
Associate Professor
The University of Texas MD Anderson Cancer Center
Yesid Alvarado Valero
Associate Professor
The University of Texas MD Anderson Cancer Center
Tapan M. Kadia
The University of Texas MD Anderson Cancer Center
Elias J. Jabbour
Professor
The University of Texas MD Anderson Cancer Center
Courtney D. DiNardo
University of Pennsylvania
Guillermo Garcia-Manero
The University of Texas MD Anderson Cancer Center
Naval G. Daver
Professor of Medicine
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.